Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Ted Yednock, Executive Vice President and Chief Innovation Officer at Annexon, Inc. (NASDAQ:ANNX), sold 1,116 shares of common stock on July 14, 2025, for approximately $2,879. The sales were executed in multiple trades with prices ranging from $2.57 to $2.64. The transaction comes as the stock has declined nearly 10% over the past week, though InvestingPro analysis suggests the company is currently undervalued.
Following the transaction, Yednock directly owns 105,084 shares of Annexon. The company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 8.0, according to InvestingPro data.
The shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. While analysts maintain a bullish consensus on the stock with price targets ranging from $9 to $14, InvestingPro subscribers can access 8 additional key insights about Annexon’s financial health and market position.
In other recent news, Annexon, Inc. has amended certain common stock purchase warrants originally issued in July 2022, extending their term by one year to June 30, 2026. These warrants, exercisable for up to 6,877,622 shares, are now limited to cash transactions at a price of $5.806875 per share. If fully exercised, Annexon could receive approximately $39.9 million in proceeds. In clinical developments, Annexon announced positive results for its lead investigational therapy, tanruprubart, which showed significant benefits over standard care for Guillain-Barré Syndrome at the Peripheral Nerve Society Annual Meeting. Tanruprubart-treated patients experienced rapid and sustained recovery, with improvements in muscle strength as early as Week 1. Furthermore, Cantor Fitzgerald has maintained an Overweight rating on Annexon, highlighting the significance of its financial position and the potential approval of ANX005 for Guillain-Barré Syndrome. The firm also noted Annexon’s approximately $264 million in cash reserves, which could support the development and commercialization of its therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.